In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer

Cancer Research

Volumn 74, Issue 22, 2014, Pages 6565-6577

  Santos, Mirentxu ^a,b   Martínez Fernández, Mónica ^a,b   Dueñas, Marta ^a,b   García Escudero, Ramón ^a,b   Alfaya, Begoña ^a   Villacampa, Felipe ^b   Saiz Ladera, Cristina ^a   Costa, Clotilde ^a   Oteo, Marta ^a,b   Duarte, José ^b   Martínez, Victor ^b   Gómez Rodriguez, Ma José ^b   Martín, Ma Luisa ^b   Fernández, Manoli ^b   Viatour, Patrick ^c,d   Morcillo, Miguel A ^a,b   Sage, Julien ^c   Castellano, Daniel ^b   Rodriguez Peralto, Jose L ^b   De La Rosa, Federico ^b   Paramio, Jesús M ^a,b   more..

^a CIEMAT   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c STANFORD UNIVERSITY   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTOME; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER MODEL; CANCER RECURRENCE; CONTROLLED STUDY; E2F GENE; EZH2 GENE; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE LOSS; GENE REPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; RB GENE; TRANSCRIPTOMICS; ANIMAL; DISEASE COURSE; GENETICS; MOUSE; NEOPLASM RECURRENCE, LOCAL; PHYSIOLOGY; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

ANIMALS; DISEASE PROGRESSION; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM RECURRENCE, LOCAL; POLYCOMB REPRESSIVE COMPLEX 2; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TRANSCRIPTOME; URINARY BLADDER NEOPLASMS;

EID: 84918529219     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1218     Document Type: Article

References (48)

1. Wu X, Hildebrandt MA, Chang DW. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev 2009;28:269-80.
2. Gallagher DJ, Milowsky MI. Bladder cancer. Curr Treat Options Oncol 2009;10:205-15.
3. Burger M, Oosterlinck W, Konety B, Chang S, Gudjonsson S, Pruthi R, et al. ICUD-EAU International consultation on bladder cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. European Urol 2013;63:36-44.
4. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361-73.
5. Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I, Balar AV, et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013;31:3133-40.
6. Rebouissou S, Herault A, Letouze E, Neuzillet Y, Laplanche A, Ofualuka K, et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J Pathol 2012;227:315-24.
7. Van Rhijn BW. Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer. Urol Oncol 2012;30:518-23.
8. Lindgren D, Sjodahl G, Lauss M, Staaf J, Chebil G, Lovgren K, et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One 2012;7:e38863.
9. Duenas M, Martinez-Fernandez M, Garcia-Escudero R, Villacampa F, Marques M, Saiz-Ladera C, et al. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in nonmuscle invasive tumors. Mol Carcinog 2013 Dec. 18 [Epub ahead of print], doi: 10.1002/mc.22125.
10. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.
11. Ahmad I, Sansom OJ, Leung HY. Exploring molecular genetics of bladder cancer: lessons learned from mouse models. Dis Mod Mech 2012;5:323-32.
12. He F, Mo L, Zheng XY, Hu C, Lepor H, Lee EY, et al. Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res 2009;69:9413-21.
13. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009;23:675-80.
14. Ruiz S, Santos M, Segrelles C, Leis H, Jorcano JL, Berns A, et al. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development 2004;131:2737-48.
15. Liang FX, Bosland MC, Huang H, Romih R, Baptiste S, Deng FM, et al. Cellular basis of urothelial squamous metaplasia: roles of lineage heterogeneity and cell replacement. J Cell Biol 2005;171:835-44.
16. Costa C, Santos M, Segrelles C, Duenas M, Lara MF, Agirre X, et al. A novel tumor suppressor network in squamous malignancies. Sci Rep 2012;2:828.
17. Costa C, Santos M, Martinez-Fernandez M, Duenas M, Lorz C, Garcia-Escudero R, et al. E2F1 loss induces spontaneous tumour development in Rb-deficient epidermis. Oncogene 2013;32:2937-51.
18. Lara MF, Garcia-Escudero R, Ruiz S, Santos M, Moral M, Martinez-Cruz AB, et al. Gene profiling approaches help to define the specific functions of retinoblastoma family in epidermis. Mol Carcinog 2008;47:209-21.
19. Costa C, Paramio JM, Santos M. Skin tumors Rb (eing) uncovered. Front Oncol 2013;3:307.
20. Viatour P, Somervaille TC, Venkatasubrahmanyam S, Kogan S, McLaughlin ME, Weissman IL, et al. Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family. Cell Stem Cell 2008;3:416-28.
21. Bornachea O, Santos M, Martinez-Cruz AB, Garcia-Escudero R, Duenas M, Costa C, et al. EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours. Sci Rep 2012;2:434.
22. Duenas M, Santos M, Aranda JF, Bielza C, Martinez-Cruz AB, Lorz C, et al. Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. PLoS One 2012;7:e42494.
23. Ohl F, Jung M, Radonic A, Sachs M, Loening SA, Jung K. Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. J Urol 2006;175:1915-20.
24. Lachmann A, Xu H, Krishnan J, Berger SI, Mazloom AR, Ma'ayan A. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics (Oxford, England) 2010;26:2438-44.
25. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated datamining platform. Neoplasia 2004;6:1-6.
26. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 2010;28:2660-7.
27. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33:90-6.
28. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Embo J 2003;22:5323-35.
29. Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Marquez M, Vazquez M, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 2013;45:1464-9.
30. Ross JS, Wang K, Al-Rohil RN, Nazeer T, Sheehan CE, Otto GA, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol 2014;27:271-80.
31. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013;45:1459-63.
32. Cazier JB, Rao SR, McLean CM, Walker AL, Wright BJ, Jaeger EE, et al. Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nat Commun 2014;5:3756.
33. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011;43:875-8.
34. Garcia-Espana A, Salazar E, Sun TT, Wu XR, Pellicer A. Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior. Cancer Res 2005;65:1150-7.
35. Martinez-Cruz AB, Santos M, Lara MF, Segrelles C, Ruiz S, Moral M, et al. Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res 2008;68:683-92.
36. Ho PL, Lay EJ, Jian W, Parra D, Chan KS. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res 2012;72:3135-42.
37. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005;24:5218-25.
38. Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, et al. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int 2012;110:E1237-48.
39. Olsson AY, Feber A, Edwards S, Te Poele R, Giddings I, Merson S, et al. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene 2007;26:1028-37.
40. Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene 2008;27:2716-27.
41. Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004;23:5616-23.
42. Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 2004;23:1627-30.
43. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 2004;23:5871-9.
44. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007;21:1050-63.
45. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108-12.
46. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012;8:890-6.
47. Weikert S, Christoph F, Kollermann J, Muller M, Schrader M, Miller K, et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 2005;16:349-53.
48. Wang H, Albadine R, Magheli A, Guzzo TJ, Ball MW, Hinz S, et al. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol Oncol 2012;30:428-33.